
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.

Mr Komarov is a junior business analyst at Lifescience Dynamics in London with consulting experience across neurology and neuropsychiatry, with particular depth in major depressive disorder. He holds an MSc in Biotechnology and Pharmaceutical Management from University College London, where he conducted research on venture capital theory in CNS-focused biotech start-ups.

Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.